A Phase 2 interventional study of GSK1265744 30mg and Placebo in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-12-06.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo.
The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is needed after Part 1, about 6 people will take part in Part 2 of the study receiving dose B.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 9 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
Exclusion Criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Note: One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
Note: Study medications refer to GSK1265744 or placebo.
Exclusion Criteria for Screening ECG:
Males Females Heart rate \<45 and >100 bpm \<50 and >100 bpm QRS duration >120 msec >120 msec (Bazett) > 450 msec > 450 msec Non-sustained (≥ 3 consecutive beats) or sustained ventricular tachycardia. Sinus Pauses >3 seconds. 2nd degree (Type II) or higher AV block. Evidence of previous myocardial infarction (pathologic Q waves, S-T segment changes (except early repolarization)).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GSK1265744 30 mg
Drug: GSK1265744 30mg
Placebo to match GSK1265744
Drug: Placebo
GSK1265744 5 mg
Drug: GSK1265744 5mg
GSK1265744 30 mg
Placebo to match GSK1265744
GSK1265744 5mg
Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a lower limit of detection (LLOD) of 50 copies/milliliter (mL) (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 11
GSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24])
Blood samples for PK analysis of AUC(0-24) of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
Time frame: Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
GSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24)
Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
Time frame: Day 1 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
GSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau])
Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
GSK1265744 PK Parameters Following Dose Administration on Day 10: Predose Concentration (C0), Concentration at End of Dosing Interval (Ctau), Minimum Observed Concentration During One Dosing Interval (Cmin)
Blood samples for PK analysis of C0, Ctau and Cmin of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Maximum Observed Concentration (Cmax)
Blood samples for PK analysis of Cmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10
GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Time to Cmax (Tmax)
Blood samples for PK analysis of tmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
Time frame: Pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10
GSK1265744 PK Parameters Following Dose Administration on Day 1 and Day 10: Terminal Half-life (t1/2) and Absorption Lag Time (Tlag)
PK sampling was planned to be collected up to 24 hours only on Day 1 and Day 10. The data for this outcome measure was however not collected.
Time frame: Day 1 and Day 10
GSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F)
Blood samples for PK analysis of CL/F of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
Time frame: Day 10 (Pre-dose [within 15 minutes prior to dosing] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose)
Number of Participants With Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or is associated with liver injury and impaired liver function.
Time frame: Day 1 to Day 11
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (ANC- Absolute Neutrophil Count), White Blood Cell Count
Blood samples for assessment of hematology parameters of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC- absolute neutrophil count) and white blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Hemoglobin
Blood samples for assessment of hematology parameter of hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Mean Corpuscle Hemoglobin
Blood samples for assessment of hematology parameter of mean corpuscle hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Mean Corpuscle Volume
Blood samples for assessment of hematology parameter of mean corpuscle volume was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Platelet Count
Blood samples for assessment of hematology parameter of platelet count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Red Blood Cell Count
Blood samples for assessment of hematology parameter of red blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Hematology Parameters: Reticulocytes
Blood samples for assessment of hematology parameter of reticulocytes was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Clinical Chemistry Data: Albumin, Total Protein
Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Clinical Chemistry Data: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Lipase
Blood samples for assessment of clinical chemistry parameters of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and lipase was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Direct Bilirubin, Total Bilirubin, Calcium, Cholesterol, Creatinine, Glucose, High Density Lipoprotein (HDL) Cholesterol Direct, Low Density Lipoprotein (LDL) Cholesterol Calculation, Triglycerides, Urea/Blood Urea Nitrogen
Blood samples for assessment of clinical chemistry parameters of direct bilirubin, total bilirubin, calcium, cholesterol, creatinine, glucose, HDL cholesterol direct, LDL cholesterol calculation, triglycerides,Urea/BUN was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Change From Baseline in Clinical Chemistry Data: Chloride, Carbon Dioxide Content/Bicarbonate, Magnesium, Sodium, Potassium
Blood samples for assessment of clinical chemistry parameters of chloride, carbon dioxide content/bicarbonate, magnesium, sodium and potassium was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 3, 7, 10
Number of Participants With Urinalysis Data
Samples for urinalysis assessment was collected on Day 1, Day 3 and Day 10. Urinalysis parameters included urine bilirubin, urine occult blood, urine glucose, urine ketones, urine nitrite, urine pH, urine protein, urine specific gravity and urine leukocyte esterase test for detecting white blood cell.
Time frame: Day 1 to Day 10
Change From Baseline in Vital Sign: Systolic and Diastolic Blood Pressure
Systolic and diastolic blood pressure was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Change From Baseline in Vital Sign: Heart Rate
Heart rate was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Change From Baseline in Electrocardiogram (ECG) Parameters
All ECGs were obtained after a minimum 10 minute rest in a semi-supine position. The 12-lead ECGs were obtained at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10 using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and Bazett's correction (QTcB) and Fridericia correction (QTcF) intervals. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1, pre-dose) and Day 1 (2 hours post dose), 4, 7, 10
Change From Baseline in Plasma HIV-1 RNA
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA were collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1 pre-dose) and Day 1 (post dose), 2, 3, 4, 7, 8, 9, 10
Change From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Nadir was the maximum change from Baseline in plasma HIV-1 RNA. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 11
Plasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Estimated mean rate of decline (i.e., slope of day) with corresponding 90% confidence interval was provided for each treatment.
Time frame: Up to Day 10
Number of Participants With HIV-1 RNA<400 Copies/mL
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.
Time frame: Up to Day 11
Number of Participants With HIV-1 RNA<50 Copies/mL
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.
Time frame: Up to Day 11
Change From Baseline in CD4+ Cell Count to Day 11
Whole venous blood samples was obtained from each participant for the analysis of lymphocyte subsets by flow cytometry on Day 1 and Day 11. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Time frame: Baseline (Day 1) and Day 11
Pre-morning Dose Concentrations (C0) on Day 2 Through 10 to Assess the Achievement of Steady State of GSK1265744 Following Repeat Administration
Steady state is said to be reached, when the pre-dose concentration slope estimate is close to zero. The data for pre-dose concentration on Day 1 24 hours (Day 2) through Day 10 has been presented.
Time frame: Day 1 24 hours (Day 2), Pre-dose on Days 3, 4, 7, 8, 9 and 10
Accumulation Ratios for AUC, Cmax, and Ctau
The accumulation ratio was calculated as the ratio of AUC(0-τ), Cmax, and Ctau on Day 10 to AUC(0-24), Cmax, and C24 on Day 1 for each participant. The ratio of geometric least square means of each parameter on Day 10 to Day 1 was presented along with 90% confidence interval.
Time frame: Days 1 and 10
Day 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (AUC\[0-24\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
Time frame: Day 1
Day 1 Cmax and C24 at Different Doses for the Assessment of Dose Proportionality Using Power Model
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (Cmax, and C24) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
Time frame: Day 1
Day 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (AUC\[0-tau\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
Time frame: Day 10
Day 10 Cmax, C0 and Ctau at Different Doses for the Assessment of Dose Proportionality Using Power Model
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (Cmax, Ctau and C0) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
Time frame: Day 10
This study was conducted at 4 centers in the United States from 09 June 2009 to 13 August 2009.
| Milestone | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Optimized Therapy |
|---|---|---|---|---|
| Started | 8 | 0 | 0 | 0 |
| Completed | 7 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Optimized Therapy |
|---|---|---|---|---|
| Started | 0 | 7 | 2 | 0 |
| Completed | 0 | 7 | 2 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Optimized Therapy |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 |
| Completed | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a lower limit of detection (LLOD) of 50 copies/milliliter (mL) (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| log10 copies/mL | GSK1265744 5 mg | Placebo |
|---|---|---|
| Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11 | -2.169 ± 0.2405 | -0.092 ± 0.1499 |
Blood samples for PK analysis of AUC(0-24) of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
| Hour*microgram per milliliter (hr*µg/mL) | GSK1265744 5 mg |
|---|---|
| GSK1265744 Pharmacokinetic (PK) Parameters Following Dose Administration on Day 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments(AUC[0-24]) | 7.53 ± 23 |
Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 1 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
| Micrograms per milliliter (µg/mL) | GSK1265744 5 mg |
|---|---|
| GSK1265744 PK Parameters Following Dose Administration on Day 1: Concentration at 24 Hours Post Dose (C24) | 0.23 ± 28 |
Blood samples for PK analysis of C24 of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.
| hr*µg/mL | GSK1265744 5 mg |
|---|---|
| GSK1265744 PK Parameters Following Dose Administration on Day 10: Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) | 17.74 ± 31 |
Blood samples for PK analysis of C0, Ctau and Cmin of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
| µg/mL | GSK1265744 5 mg |
|---|---|
| C0 | 0.54 ± 36 |
| Ctau | 0.57 ± 33 |
| Cmin | 0.53 ± 35 |
Blood samples for PK analysis of Cmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
| µg/mL | GSK1265744 5 mg |
|---|---|
| Day 1 | 0.52 ± 20 |
| Day 10 | 1.02 ± 25 |
Blood samples for PK analysis of tmax of GSK1265744 was collected at pre-dose (within 15 minutes prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose on Days 1 and 10. Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
| Hour | GSK1265744 5 mg |
|---|---|
| Day 1 | 2.00 (1.00 to 4.08) |
| Day 10 | 2.00 (1.50 to 4.08) |
PK sampling was planned to be collected up to 24 hours only on Day 1 and Day 10. The data for this outcome measure was however not collected.
No measurements were reported for this outcome.
Blood samples for PK analysis of CL/F of GSK1265744 was collected on Day 10 (Pre-dose \[within 15 minutes prior to dosing\] and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8hours post-dose). Samples were collected at nominal times relative to the proposed time of GSK1265744 dosing. The actual date and time of each blood sample collection was recorded.
| Liter per hour (L/hr) | GSK1265744 5 mg |
|---|---|
| GSK1265744 PK Parameters Following Last Repeat Administration on Day 10: Apparent Clearance Following Oral Dosing (CL/F) | 0.28 ± 31 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or is associated with liver injury and impaired liver function.
| Participants | GSK1265744 5 mg | Placebo | Optimized Therapy |
|---|---|---|---|
| Any AEs | 0 | 2 | 3 |
| Any SAEs | 0 | 0 | 0 |
Blood samples for assessment of hematology parameters of basophils, eosinophils, lymphocytes, monocytes, total neutrophils (ANC- absolute neutrophil count) and white blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Thousand cells per microliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Basophils, Day 3 | 0.017 ± 0.0287 | 0.005 ± 0.0071 |
| Basophils, Day 7 | 0.007 ± 0.0125 | 0.015 ± 0.0071 |
| Basophils, Day 10 | 0.009 ± 0.0146 | 0.020 ± 0.0000 |
| Eosinophils, Day 3 | -0.024 ± 0.0408 | 0.250 ± 0.4101 |
| Eosinophils, Day 7 | -0.039 ± 0.0498 | 0.325 ± 0.5869 |
| Eosinophils, Day 10 | -0.009 ± 0.0628 | -0.055 ± 0.1485 |
| Lymphocytes, Day 3 | 0.197 ± 0.2870 | -0.500 ± 0.3111 |
| Lymphocytes, Day 7 | 0.190 ± 0.2514 | -0.525 ± 0.1485 |
| Lymphocytes, Day 10 | 0.229 ± 0.2738 | -0.720 ± 0.5515 |
| Monocytes, Day 3 | -0.030 ± 0.0876 | 0.170 ± 0.2121 |
| Monocytes, Day 7 | -0.039 ± 0.1126 | 0.035 ± 0.1626 |
| Monocytes, Day 10 | 0.056 ± 0.0774 | -0.005 ± 0.2192 |
| Total Neutrophils, Day 3 | 0.181 ± 0.6097 | -0.080 ± 0.1273 |
| Total Neutrophils, Day 7 | -0.003 ± 0.6304 | -0.155 ± 0.2192 |
| Total Neutrophils, Day 10 | 0.831 ± 1.6043 | 0.405 ± 1.1384 |
| White blood cell count, Day 3 | 0.34 ± 0.282 | -0.15 ± 1.061 |
| White blood cell count, Day 7 | 0.11 ± 0.782 | -0.30 ± 1.131 |
| White blood cell count, Day 10 | 1.11 ± 1.508 | -0.35 ± 1.626 |
Blood samples for assessment of hematology parameter of hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Grams per deciliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | 0.13 ± 0.637 | -0.30 ± 0.424 |
| Day 7 | 0.06 ± 0.519 | 0.00 ± 0.424 |
| Day 10 | -0.17 ± 0.446 | -0.15 ± 0.354 |
Blood samples for assessment of hematology parameter of mean corpuscle hemoglobin was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Picogram | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | -0.03 ± 0.198 | 0.25 ± 0.495 |
| Day 7 | 0.37 ± 0.411 | 0.30 ± 0.141 |
| Day 10 | 0.00 ± 0.306 | 0.40 ± 0.424 |
Blood samples for assessment of hematology parameter of mean corpuscle volume was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Femtoliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | 1.0 ± 1.15 | 0.5 ± 0.71 |
| Day 7 | 1.0 ± 1.63 | -0.5 ± 0.71 |
| Day 10 | 1.7 ± 1.11 | 0.0 ± 1.41 |
Blood samples for assessment of hematology parameter of platelet count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Cells per cubic millimeter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | 10428.6 ± 8847.92 | 5000.0 ± 21213.20 |
| Day 7 | 15142.9 ± 29299.76 | 2500.0 ± 2121.32 |
| Day 10 | 8000.0 ± 23860.71 | 9500.0 ± 37476.66 |
Blood samples for assessment of hematology parameter of red blood cell count was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Million cells per microliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | 0.03 ± 0.221 | -0.15 ± 0.071 |
| Day 7 | -0.06 ± 0.151 | -0.05 ± 0.071 |
| Day 10 | -0.09 ± 0.135 | -0.10 ± 0.141 |
Blood samples for assessment of hematology parameter of reticulocytes was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Giga cells per liter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 3 | 5.51 ± 9.971 | 9.45 ± 1.768 |
| Day 7 | 13.79 ± 27.361 | -6.50 ± 0.849 |
| Day 10 | 13.79 ± 16.419 | 21.30 ± 35.497 |
Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Grams per deciliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Albumin, Day 3 | 0.16 ± 0.162 | 0.00 ± 0.000 |
| Albumin, Day 7 | 0.08 ± 0.117 | 0.05 ± 0.071 |
| Albumin, Day 10 | 0.06 ± 0.098 | 0.15 ± 0.071 |
| Total protein, Day 3 | 0.24 ± 0.447 | 0.05 ± 0.212 |
| Total protein, Day 7 | 0.03 ± 0.294 | 0.10 ± 0.424 |
| Total protein, Day 10 | -0.10 ± 0.342 | 0.10 ± 0.000 |
Blood samples for assessment of clinical chemistry parameters of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and lipase was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Units per liter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Alkaline phosphatase, Day 3 | 1.6 ± 3.10 | -3.5 ± 4.95 |
| Alkaline phosphatase, Day 7 | 0.5 ± 3.89 | -5.0 ± 0.00 |
| Alkaline phosphatase, Day 10 | -2.4 ± 6.55 | -4.0 ± 2.83 |
| Alanine amino transferase, Day 3 | 2.9 ± 6.41 | -4.0 ± 2.83 |
| Alanine amino transferase, Day 7 | -0.2 ± 4.02 | -1.5 ± 9.19 |
| Alanine amino transferase, Day 10 | 2.0 ± 4.12 | -2.5 ± 7.78 |
| Aspartate amino transferase, Day 3 | -1.0 ± 4.28 | -2.0 ± 8.49 |
| Aspartate amino transferase, Day 7 | -1.0 ± 3.52 | -3.5 ± 7.78 |
| Aspartate amino transferase, Day 10 | 0.4 ± 5.32 | -2.0 ± 5.66 |
| Creatine kinase, Day 3 | -0.1 ± 11.42 | -29.5 ± 10.61 |
| Creatine kinase, Day 7 | 27.7 ± 77.11 | -48.0 ± 42.43 |
| Creatine kinase, Day 10 | 20.6 ± 42.97 | -40.5 ± 43.13 |
| Lipase, Day 3 | 0.9 ± 8.91 | 4.0 ± 2.83 |
| Lipase, Day 7 | -0.9 ± 17.22 | -1.0 ± 8.49 |
| Lipase, Day 10 | 0.3 ± 14.42 | -2.0 ± 2.83 |
Blood samples for assessment of clinical chemistry parameters of direct bilirubin, total bilirubin, calcium, cholesterol, creatinine, glucose, HDL cholesterol direct, LDL cholesterol calculation, triglycerides,Urea/BUN was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Milligrams per deciliter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Direct bilirubin, Day 3 | -0.04 ± 0.113 | -0.05 ± 0.071 |
| Direct bilirubin, Day 7 | -0.10 ± 0.126 | -0.05 ± 0.071 |
| Direct bilirubin, Day 10 | -0.06 ± 0.053 | 0.00 ± 0.000 |
| Total bilirubin, Day 3 | -0.06 ± 0.207 | -0.25 ± 0.354 |
| Total bilirubin, Day 7 | -0.03 ± 0.186 | -0.40 ± 0.566 |
| Total bilirubin, Day 10 | 0.00 ± 0.216 | -0.10 ± 0.141 |
| Calcium, Day 3 | 0.13 ± 0.198 | 0.00 ± 0.141 |
| Calcium, Day 7 | 0.17 ± 0.207 | 0.05 ± 0.495 |
| Calcium, Day 10 | -0.09 ± 0.254 | 0.20 ± 0.000 |
| Cholesterol, Day 3 | 5.7 ± 8.90 | -7.5 ± 9.19 |
| Cholesterol, Day 7 | 16.2 ± 32.60 | 0.0 ± 1.41 |
| Cholesterol, Day 10 | 4.0 ± 13.17 | 1.0 ± 2.83 |
| Creatinine, Day 3 | 0.03 ± 0.049 | 0.05 ± 0.071 |
| Creatinine, Day 7 | 0.05 ± 0.105 | 0.05 ± 0.071 |
| Creatinine, Day 10 | 0.03 ± 0.076 | 0.05 ± 0.071 |
| Glucose, Day 3 | 16.1 ± 28.35 | 2.0 ± 1.41 |
| Glucose, Day 7 | -16.5 ± 45.62 | 4.5 ± 3.54 |
| Glucose, Day 10 | 0.1 ± 5.81 | -4.0 ± 0.00 |
| HDL cholesterol, direct, Day 3 | -0.6 ± 2.44 | -1.5 ± 2.12 |
| HDL cholesterol, direct, Day 7 | -0.2 ± 9.62 | 0.5 ± 0.71 |
| HDL cholesterol, direct, Day 10 | 1.9 ± 4.56 | -2.0 ± 1.41 |
| LDL cholesterol calculation, Day 3 | 6.7 ± 9.21 | -7.0 ± 12.73 |
| LDL cholesterol calculation, Day 7 | -0.2 ± 9.93 | 3.5 ± 6.36 |
| LDL cholesterol calculation, Day 10 | 1.6 ± 10.42 | -2.5 ± 16.26 |
| Triglycerides, Day 3 | -1.9 ± 49.69 | 5.0 ± 4.24 |
| Triglycerides, Day 7 | 258.3 ± 636.46 | -20.5 ± 21.92 |
| Triglycerides, Day 10 | 3.6 ± 39.59 | 28.5 ± 72.83 |
| Urea/BUN, Day 3 | 1.4 ± 2.15 | -1.0 ± 5.66 |
| Urea/BUN, Day 7 | 1.3 ± 3.27 | -2.5 ± 4.95 |
| Urea/BUN, Day 10 | 0.7 ± 2.81 | -2.0 ± 0.00 |
Blood samples for assessment of clinical chemistry parameters of chloride, carbon dioxide content/bicarbonate, magnesium, sodium and potassium was collected at Baseline, Day 3, 7 and 10. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Milliequivalents per liter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Chloride, Day 3 | 0.0 ± 0.82 | 2.0 ± 0.00 |
| Chloride, Day 7 | -0.2 ± 2.79 | 2.0 ± 0.00 |
| Chloride, Day 10 | -0.7 ± 2.69 | 2.0 ± 4.24 |
| Carbon dioxide content/Bicarbonate, Day 3 | -0.9 ± 2.41 | -1.0 ± 0.00 |
| Carbon dioxide content/Bicarbonate, Day 7 | -1.3 ± 1.63 | -2.0 ± 2.83 |
| Carbon dioxide content/Bicarbonate, Day 10 | 0.6 ± 2.76 | -2.0 ± 2.83 |
| Potassium, Day 3 | 0.20 ± 0.200 | 0.30 ± 0.141 |
| Potassium, Day 7 | 0.00 ± 0.245 | 0.20 ± 0.283 |
| Potassium, Day 10 | 0.07 ± 0.368 | 0.05 ± 0.212 |
| Magnesium, Day 3 | -0.04 ± 0.098 | 0.10 ± 0.000 |
| Magnesium, Day 7 | -0.00 ± 0.089 | 0.10 ± 0.141 |
| Magnesium, Day 10 | -0.04 ± 0.098 | 0.00 ± 0.141 |
| Sodium, Day 3 | -0.4 ± 1.62 | 0.5 ± 0.71 |
| Sodium, Day 7 | 0.3 ± 2.50 | 0.5 ± 0.71 |
| Sodium, Day 10 | -0.4 ± 1.62 | 0.5 ± 2.12 |
Samples for urinalysis assessment was collected on Day 1, Day 3 and Day 10. Urinalysis parameters included urine bilirubin, urine occult blood, urine glucose, urine ketones, urine nitrite, urine pH, urine protein, urine specific gravity and urine leukocyte esterase test for detecting white blood cell.
| Participants | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 1, Urine Bilirubin, Negative | 7 | 2 |
| Day 1, Urine Occult Blood, Negative | 7 | 2 |
| Day 1, Urine Glucose, Negative | 7 | 2 |
| Day 1, Urine Ketones, Negative | 7 | 2 |
| Day 1, Urine Nitrite, Negative | 6 | 2 |
| Day 1, Urine Nitrite, Positive | 1 | 0 |
| Day 1, Urine pH, 5.5 | 2 | 1 |
| Day 1, Urine pH, 6 | 4 | 1 |
| Day 1, Urine pH, 6.5 | 1 | 0 |
| Day 1, Urine Protein, Negative | 7 | 2 |
| Day 1, Urine Specific Gravity, 1.006 | 1 | 0 |
| Day 1, Urine Specific Gravity, 1.014 | 0 | 1 |
| Day 1, Urine Specific Gravity, 1.015 | 0 | 1 |
| Day 1, Urine Specific Gravity, 1.017 | 1 | 0 |
| Day 1, Urine Specific Gravity, 1.019 | 2 | 0 |
| Day 1, Urine Specific Gravity, 1.021 | 1 | 0 |
| Day 1, Urine Specific Gravity, 1.025 | 1 | 0 |
| Day 1, Urine Specific Gravity, 1.03 | 1 | 0 |
| Day 1, ULET for white blood cell, Negative | 7 | 2 |
| Day 3, Urine Bilirubin, Negative | 7 | 2 |
| Day 3, Urine Occult Blood, Negative | 6 | 2 |
| Day 3, Urine Occult Blood, 1+ | 1 | 0 |
| Day 3, Urine Glucose, 3+ | 1 | 0 |
| Day 3, Urine Glucose, Negative | 6 | 2 |
| Day 3, Urine Ketones, Negative | 7 | 2 |
| Day 3, Urine Nitrite, Negative | 6 | 2 |
| Day 3, Urine Nitrite, Positive | 1 | 0 |
| Day 3, Urine pH, 5.5 | 4 | 1 |
| Day 3, Urine pH, 6 | 2 | 1 |
| Day 3, Urine pH, 6.5 | 1 | 0 |
| Day 3, Urine Protein, Negative | 6 | 2 |
| Day 3, Urine Protein, Trace | 1 | 0 |
| Day 3, Urine Specific Gravity, 1.016 | 1 | 0 |
| Day 3, Urine Specific Gravity, 1.017 | 1 | 1 |
| Day 3, Urine Specific Gravity, 1.018 | 0 | 1 |
| Day 3, Urine Specific Gravity, 1.021 | 2 | 0 |
| Day 3, Urine Specific Gravity, 1.022 | 1 | 0 |
| Day 3, Urine Specific Gravity, 1.027 | 1 | 0 |
| Day 3, Urine Specific Gravity, 1.03 | 1 | 0 |
| Day 3, ULET for white blood cell, 2+ | 1 | 0 |
| Day 3, ULET for white blood cell, Negative | 6 | 2 |
| Day 10, Urine Bilirubin, Negative | 7 | 2 |
| Day 10, Urine Occult Blood, 2+ | 1 | 0 |
| Day 10, Urine Occult Blood, Negative | 6 | 2 |
| Day 10, Urine Glucose, Negative | 7 | 2 |
| Day 10, Urine Ketones, Negative | 7 | 2 |
| Day 10, Urine Nitrite, Negative | 6 | 2 |
| Day 10, Urine Nitrite, Positive | 1 | 0 |
| Day 10, Urine pH, 5.5 | 0 | 1 |
| Day 10, Urine pH, 6 | 4 | 1 |
| Day 10, Urine pH, 6.5 | 3 | 0 |
| Day 10, Urine Protein, Negative | 5 | 2 |
| Day 10, Urine Protein, Trace | 2 | 0 |
| Day 10, Urine Specific Gravity, 1.009 | 0 | 1 |
| Day 10, Urine Specific Gravity, 1.016 | 0 | 1 |
| Day 10, Urine Specific Gravity, 1.02 | 1 | 0 |
| Day 10, Urine Specific Gravity, 1.021 | 1 | 0 |
| Day 10, Urine Specific Gravity, 1.023 | 1 | 0 |
| Day 10, Urine Specific Gravity, 1.025 | 2 | 0 |
| Day 10, Urine Specific Gravity, 1.027 | 1 | 0 |
| Day 10, Urine Specific Gravity, 1.03 | 1 | 0 |
| Day 10, ULET for white blood cell, Negative | 7 | 2 |
Systolic and diastolic blood pressure was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Millimeters of mercury (mmHg) | GSK1265744 5 mg | Placebo |
|---|---|---|
| Systolic blood pressure, Day 1, 2 Hours | 1.2 ± 8.59 | 5.8 ± 0.35 |
| Systolic blood pressure, Day 4, Pre dose | 1.8 ± 9.16 | 5.8 ± 3.18 |
| Systolic blood pressure, Day 7, Pre dose | -2.5 ± 11.22 | -4.3 ± 8.84 |
| Systolic blood pressure, Day 10, Pre dose | 0.6 ± 19.19 | 19.8 ± 14.50 |
| Systolic blood pressure, Day 10, 2 Hours | -0.2 ± 10.59 | 13.3 ± 4.60 |
| Diastolic blood pressure, Day 1, 2 Hours | -5.7 ± 5.76 | -0.5 ± 2.12 |
| Diastolic blood pressure, Day 4, Pre dose | -2.4 ± 8.91 | -2.5 ± 10.61 |
| Diastolic blood pressure, Day 7, Pre dose | -1.6 ± 9.28 | -5.0 ± 15.56 |
| Diastolic blood pressure, Day 10, Pre dose | -5.4 ± 13.85 | 8.5 ± 14.85 |
| Diastolic blood pressure, Day 10, 2 Hours | -2.4 ± 6.82 | 6.5 ± 9.19 |
Heart rate was measured at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Beats per minute | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 1, 2 Hours | -7.0 ± 2.10 | -5.8 ± 4.60 |
| Day 4, Pre dose | 5.3 ± 6.24 | -5.8 ± 1.06 |
| Day 7, Pre dose | 6.3 ± 5.71 | -1.8 ± 1.77 |
| Day 10, Pre dose | 0.0 ± 6.74 | 5.8 ± 4.60 |
| Day 10, 2 Hours | -7.6 ± 5.12 | -10.8 ± 3.18 |
All ECGs were obtained after a minimum 10 minute rest in a semi-supine position. The 12-lead ECGs were obtained at Baseline (Day 1 pre-dose), 2 hour post dose on Day 1, pre-dose on Day 4, 7, 10 and 2 hours post dose on Day 10 using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and Bazett's correction (QTcB) and Fridericia correction (QTcF) intervals. Baseline was defined at Day 1 pre-dose. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Milliseconds (msec) | GSK1265744 5 mg | Placebo |
|---|---|---|
| PR, Day 1, 2 Hours | 0.0 ± 1.83 | 1.0 ± 2.83 |
| PR, Day 4, Pre dose | 4.0 ± 5.42 | 5.0 ± 11.31 |
| PR, Day 7, Pre dose | -0.9 ± 4.67 | 0.0 ± 12.73 |
| PR, Day 10, Pre dose | -1.7 ± 3.04 | 0.0 ± 9.90 |
| PR, Day 10, 2 Hours | 4.3 ± 10.09 | 4.0 ± 12.73 |
| QRS, Day 1, 2 Hours | -0.7 ± 3.68 | 1.5 ± 0.71 |
| QRS, Day 4, Pre dose | 0.7 ± 2.36 | -3.5 ± 12.02 |
| QRS, Day 7, Pre dose | -0.1 ± 4.26 | 3.5 ± 2.12 |
| QRS, Day 10, Pre dose | 1.0 ± 5.07 | 0.5 ± 3.54 |
| QRS, Day 10, 2 Hours | -0.7 ± 8.99 | 5.5 ± 4.95 |
| QT, Day 1, 2 Hours | 18.1 ± 8.07 | 27.0 ± 24.04 |
| QT, Day 4, Pre dose | -10.7 ± 20.93 | 5.0 ± 7.07 |
| QT, Day 7, Pre dose | -13.6 ± 13.13 | 11.0 ± 1.41 |
| QT, Day 10, Pre dose | -3.3 ± 14.14 | -11.0 ± 24.04 |
| QT, Day 10, 2 Hours | 19.0 ± 22.15 | 25.0 ± 24.04 |
| QTcB, Day 1, 2 Hours | 0.2 ± 13.50 | 6.0 ± 4.09 |
| QTcB, Day 4, Pre dose | 2.0 ± 16.15 | -17.9 ± 2.20 |
| QTcB, Day 7, Pre dose | -0.0 ± 16.95 | -9.0 ± 25.73 |
| QTcB, Day 10, Pre dose | 1.4 ± 16.59 | -15.6 ± 10.35 |
| QTcB, Day 10, 2 Hours | -2.4 ± 12.35 | -18.1 ± 0.42 |
| QTcF, Day 1, 2 Hours | 6.4 ± 11.45 | 13.3 ± 11.06 |
| QTcF, Day 4, Pre dose | -2.4 ± 14.27 | -10.0 ± 4.05 |
| QTcF, Day 7, Pre dose | -4.7 ± 13.05 | -2.0 ± 16.30 |
| QTcF, Day 10, Pre dose | -0.2 ± 13.17 | -13.9 ± 15.19 |
| QTcF, Day 10, 2 Hours | 4.9 ± 13.62 | -3.4 ± 7.99 |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA were collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Log10 copies/mL | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 1 | 0.000 ± 0.0000 | 0.000 ± NA |
| Day 2 | -0.126 ± 0.2255 | 0.058 ± 0.2303 |
| Day 3 | -0.618 ± 0.1341 | -0.299 ± 0.2737 |
| Day 4 | -0.830 ± 0.2424 | -0.146 ± 0.0580 |
| Day 7 | -1.577 ± 0.5498 | -0.168 ± 0.1264 |
| Day 8 | -1.935 ± 0.4717 | -0.146 ± 0.2779 |
| Day 9 | -2.013 ± 0.4192 | -0.007 ± 0.1960 |
| Day 10 | -2.160 ± 0.2810 | -0.158 ± 0.1930 |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Nadir was the maximum change from Baseline in plasma HIV-1 RNA. Baseline was defined at Day 1 (pre-dose). The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| log10 copies/mL | GSK1265744 5 mg | Placebo |
|---|---|---|
| Change From Baseline in Plasma HIV-1 RNA to Nadir Over 11 Days | -2.199 ± 0.2491 | -0.418 ± 0.1058 |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Estimated mean rate of decline (i.e., slope of day) with corresponding 90% confidence interval was provided for each treatment.
| log10 copies per mL per day | GSK1265744 5 mg | Placebo |
|---|---|---|
| Plasma HIV-1 RNA Rate of Decline (Slope) Over 11 Days | -0.2313 (-0.2513 to -0.2113) | 0.0013 (-0.0233 to 0.0259) |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.
| Participants | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 7 | 2 | 0 |
| Day 8 | 4 | 0 |
| Day 9 | 4 | 0 |
| Day 10 | 5 | 0 |
| Day 11 | 5 | 0 |
Plasma for quantitative HIV-1 RNA was collected on Day 1, 2, 3, 4, 7, 8, 9, 10 and 11. On Days 1, 10 and 11, two samples for HIV-1 RNA was collected between 5-20 minutes apart to reduce sample variability. An HIV-1 RNA PCR assay with a LLOD of 50 copies/mL (ultrasensitive assay) was used for post-baseline assessments. An HIV-1 RNA PCR assay with a LLOD of 400 copies/mL (standard assay) was used for screening and Baseline assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. assessments and included a re-test with and ultrasensitive assay for all Baseline values below the LLOD. Only categories with data available at the indicated time points have been presented. Categories with null values for all the arms have not been presented.
| Participants | GSK1265744 5 mg | Placebo |
|---|---|---|
| Day 8 | 2 | 0 |
| Day 9 | 3 | 0 |
| Day 10 | 2 | 0 |
| Day 11 | 2 | 0 |
Whole venous blood samples was obtained from each participant for the analysis of lymphocyte subsets by flow cytometry on Day 1 and Day 11. Baseline was defined at Day 1. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
| Cells per cubic millimeter | GSK1265744 5 mg | Placebo |
|---|---|---|
| Change From Baseline in CD4+ Cell Count to Day 11 | 71.0 ± 56.62 | -84.0 ± 145.66 |
Steady state is said to be reached, when the pre-dose concentration slope estimate is close to zero. The data for pre-dose concentration on Day 1 24 hours (Day 2) through Day 10 has been presented.
| µg/mL | GSK1265744 5 mg |
|---|---|
| DAY 1, 24 hours (Day 2) | 0.2363 ± 0.06884 |
| DAY 3, Pre-dose | 0.3539 ± 0.12999 |
| DAY 4, Pre-dose | 0.4128 ± 0.15566 |
| DAY 7, Pre-dose | 0.5239 ± 0.11899 |
| DAY 8, Pre-dose | 0.5744 ± 0.17622 |
| DAY 9, Pre-dose | 0.5688 ± 0.16880 |
| DAY 10, Pre-dose | 0.5654 ± 0.20609 |
The accumulation ratio was calculated as the ratio of AUC(0-τ), Cmax, and Ctau on Day 10 to AUC(0-24), Cmax, and C24 on Day 1 for each participant. The ratio of geometric least square means of each parameter on Day 10 to Day 1 was presented along with 90% confidence interval.
| Ratio | GSK1265744 5 mg |
|---|---|
| Accumulation Ratio AUC | 2.355 (2.086 to 2.658) |
| Accumulation Ratio Cmax | 1.961 (1.684 to 2.283) |
| Accumulation Ratio Ctau | 2.483 (2.141 to 2.880) |
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (AUC\[0-24\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
| hr*µg/mL/mg | Pooled GSK1265744 |
|---|---|
| Day 1 AUC(0-24) at Different Doses for the Assessment of Dose Proportionality Using Power Model | 0.952 (0.802 to 1.101) |
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following single dose administration on Day 1 (Cmax, and C24) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
| μg/mL/mg | Pooled GSK1265744 |
|---|---|
| Cmax | 0.950 (0.812 to 1.088) |
| C24 | 0.949 (0.777 to 1.121) |
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (AUC\[0-tau\]) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
| hr*µg/mL/mg | Pooled GSK1265744 |
|---|---|
| Day 10 AUC(0-tau) at Different Doses for the Assessment of Dose Proportionality Using Power Model | 0.988 (0.841 to 1.135) |
Data from GSK1265744 30 mg in HIV participants (Study ITZ111451 part C HIV cohort, NCT00659191) was combined with data from this study to access dose proportionality. Dose proportionality of GSK1265744 PK parameters was assessed following a repeat dose administration on Day 10 (Cmax, Ctau and C0) using the power model. The mean slope and corresponding 90% confidence interval has been presented.
| µg/mL/mg | Pooled GSK1265744 |
|---|---|
| Cmax | 1.025 (0.903 to 1.147) |
| C0 | 0.936 (0.761 to 1.110) |
| Ctau | 0.980 (0.808 to 1.151) |
Collected over Up to follow-up visit (Day 25±1). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1265744 30 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| GSK1265744 5 mg | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Optimized Therapy | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Optimized Therapy |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/8 | 0/7 | 1/2 | 1/8 |
| Blood bilirubin increasedInvestigations | 0/8 | 0/7 | 1/2 | 1/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/8 | 0/7 | 1/2 | 0/8 |
| DizzinessNervous system disorders | 3/8 | 0/7 | 0/2 | 0/8 |
| HeadacheNervous system disorders | 2/8 | 0/7 | 0/2 | 1/8 |
| DyspepsiaGastrointestinal disorders | 2/8 | 0/7 | 0/2 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/8 | 0/7 | 0/2 | 1/8 |
| ConstipationGastrointestinal disorders | 0/8 | 0/7 | 0/2 | 1/8 |
| Ocular icterusEye disorders | 0/8 | 0/7 | 0/2 | 1/8 |
| SomnolenceNervous system disorders | 1/8 | 0/7 | 0/2 | 0/8 |
| Age, Customized(Participants) | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Total |
|---|---|---|---|---|
| 27 to 51 Years | 8 | 7 | 2 | 17 |
| Sex: Female, Male(Participants) | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 2 | 0 | 2 |
| Male | 8 | 5 | 2 | 15 |
| Race (NIH/OMB)(Participants) | GSK1265744 30 mg | GSK1265744 5 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 8 | 5 | 2 | 15 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Ran from Jun 2009 to primary completion in Aug 2009, 2 months.
Results were first posted in Dec 2017, 8 years 3 months after primary completion. A results delay was requested in Aug 2010.
Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 2 months is below that.
Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir